REGN
Regeneron Pharmaceuticals Inc
NASDAQ: REGN · HEALTHCARE · BIOTECHNOLOGY
$707.06
+3.02% today
Updated 2026-04-30
Market cap
$74.13B
P/E ratio
17.27
P/S ratio
4.97x
EPS (TTM)
$40.94
Dividend yield
0.52%
52W range
$475 – $820
Volume
0.7M
Regeneron Pharmaceuticals Inc (REGN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
29.60%
Operating margin
23.50%
ROE
14.50%
ROA
6.29%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $63.45M | $-102.34M | 64.16% | -169.13% | -161.30% |
| 2007 | $125.02M | $-105.60M | 100.00% | -91.55% | -84.46% |
| 2008 | $238.46M | $-82.71M | 99.61% | -37.67% | -34.69% |
| 2009 | $379.27M | $-67.83M | 95.80% | -19.54% | -17.88% |
| 2010 | $459.07M | $-104.47M | 99.54% | -21.23% | -22.76% |
| 2011 | $445.82M | $-221.76M | 99.05% | -46.02% | -49.74% |
| 2012 | $1.38B | $750.27M | 93.87% | 33.20% | 54.43% |
| 2013 | $2.10B | $424.36M | 92.62% | 36.11% | 20.16% |
| 2014 | $2.82B | $348.07M | 92.73% | 29.74% | 12.34% |
| 2015 | $4.10B | $636.06M | 90.43% | 30.51% | 15.50% |
| 2016 | $4.86B | $895.52M | 93.83% | 27.38% | 18.42% |
| 2017 | $5.87B | $1.20B | 93.24% | 35.41% | 20.41% |
| 2018 | $6.71B | $2.44B | 93.53% | 37.77% | 36.42% |
| 2019 | $7.86B | $2.12B | 90.05% | 28.10% | 26.91% |
| 2020 | $8.50B | $3.51B | 84.04% | 42.09% | 41.35% |
| 2021 | $16.07B | $8.08B | 83.05% | 55.67% | 50.25% |
| 2022 | $12.17B | $4.34B | 85.99% | 44.24% | 35.64% |
| 2023 | $13.12B | $3.95B | 93.26% | 30.85% | 30.14% |
| 2024 | $14.20B | $4.41B | 86.13% | 28.10% | 31.07% |
| 2025 | $14.34B | $4.50B | 85.35% | 24.95% | 31.41% |